Abstract
A late phase II study of a new camptothecin analogue, irinotecan hydrochloride (CPT-11), was conducted to evaluate the anti-tumour effect and toxicity in patients with refractory leukaemia and lymphoma including adult T-cell leukaemia (ATL)-lymphoma, in a multi-institutional cooperative study. All the patients with ATL had been previously treated with various conventional combination chemotherapies and were refractory to these therapies or had relapsed. CPT-11 was administered at a dose of 40 mg m-2 day-1 for three consecutive days repeated weekly until evidence of disease progression. One complete remission and four partial remissions were achieved in 13 assessable patients with ATL. The median total dose to achieve remission was 240 mg m-2 and the median duration of response was 31 days. The major toxicities were leucopenia (83%), diarrhoea (62%) and nausea/vomiting (69%). These were relatively severe, but they were generally tolerable and reversible. However, one patient died probably as a result of this therapy. No effective chemotherapy for adult T-cell leukaemia-lymphoma has yet been established, and the prognosis for patients with this disease is very poor. Our results suggest that CPT-11 may be a promising agent for this disease. Further combination therapy with CPT-11 is needed to improve the therapy for ATL.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Tsuda, H., Takatsuki, K., Ohno, R. et al. Treatment of adult T-cell leukaemia–lymphoma with irinotecan hydrochloride (CPT-11). Br J Cancer 70, 771–774 (1994). https://doi.org/10.1038/bjc.1994.394
Issue Date:
DOI: https://doi.org/10.1038/bjc.1994.394
This article is cited by
-
Therapeutic approaches for HTLV-1-associated adult T-cell leukemia/lymphoma: a comprehensive review
Medical Oncology (2023)
-
Adult T-Cell Leukemia: a Comprehensive Overview on Current and Promising Treatment Modalities
Current Oncology Reports (2021)
-
EPOCH regimen as salvage therapy for adult T-cell leukemia–lymphoma
International Journal of Hematology (2018)
-
Irinotecan plus cisplatin and dexamethasone (ICD) combination chemotherapy for patients with diffuse large B-cell lymphoma previously treated with Rituximab plus CHOP
Cancer Chemotherapy and Pharmacology (2008)
-
Sequential administration of irinotecan and cytarabine in the treatment of relapsed and refractory acute myeloid leukemia
Cancer Chemotherapy and Pharmacology (2006)